Wyeth Korea releases Prevenar 13

Published: 2010-06-10 06:56:00

Updated: 2010-06-10 06:56:00

Wyeth Korea said on June 7 it has launched its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]).

Prevenar 13 is indicated for active immunization for the prevention of invasive disease, penumonia, and acute otitis media caused b...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK